BELLUS HEALTH INC (BLU)
CA07987C2040 - Common Stock
Taking everything into account, BLU scores 2 out of 10 in our fundamental rating. BLU was compared to 588 industry peers in the Biotechnology industry. The financial health of BLU is average, but there are quite some concerns on its profitability. While showing a medium growth rate, BLU is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BLU has reported negative net income.
BLU had a negative operating cash flow in the past year.
In the past 5 years BLU always reported negative net income.
In the past 5 years BLU always reported negative operating cash flow.
1.2 Ratios
The profitability ratios for BLU are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLU has more shares outstanding than it did 1 year ago.
BLU has more shares outstanding than it did 5 years ago.
BLU has a worse debt/assets ratio than last year.
2.2 Solvency
BLU has an Altman-Z score of 103.35. This indicates that BLU is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BLU (103.35) is better than 99.52% of its industry peers.
BLU has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
BLU has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: BLU outperforms 47.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 103.35 |
ROIC/WACCN/A
WACC7.86%
2.3 Liquidity
BLU has a Current Ratio of 33.42. This indicates that BLU is financially healthy and has no problem in meeting its short term obligations.
BLU has a Current ratio of 33.42. This is amongst the best in the industry. BLU outperforms 97.91% of its industry peers.
BLU has a Quick Ratio of 33.42. This indicates that BLU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 33.42, BLU belongs to the top of the industry, outperforming 97.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 33.42 | ||
| Quick Ratio | 33.42 |
3. Growth
3.1 Past
BLU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.00%, which is quite good.
BLU shows a decrease in Revenue. In the last year, the revenue decreased by -6.25%.
BLU shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -34.23% yearly.
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-53.85%
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y-34.23%
Revenue growth Q2Q-25%
3.2 Future
Based on estimates for the next years, BLU will show a very strong growth in Earnings Per Share. The EPS will grow by 35.40% on average per year.
The Revenue is expected to grow by 654.86% on average over the next years. This is a very strong growth
EPS Next Y-27.52%
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
EPS Next 5Y35.4%
Revenue Next Year-35.9%
Revenue Next 2Y-19.94%
Revenue Next 3Y413.52%
Revenue Next 5Y654.86%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BLU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLU. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BLU's earnings are expected to decrease with -9.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
5. Dividend
5.1 Amount
BLU does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BELLUS HEALTH INC
NASDAQ:BLU (6/28/2023, 7:00:02 PM)
After market: 14.74 0 (0%)14.74
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.87B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 33.42 | ||
| Quick Ratio | 33.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-27.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y